KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone
Aditum Bio’s Formation of Celexor Bio
Goodwin Procter advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals. Celexor Bio is being formed in connection...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
C4 Therapeutics’ Exclusive Licensing Agreement with Betta Pharmaceuticals
Goodwin Procter served as legal counsel to C4T, and Han Kun Law Offices served as legal counsel to Betta. C4 Therapeutics, Inc. announced its exclusive licensing agreement...
Merck’s License and Collaboration Agreement with Kelun-Biotech
Morgan Lewis represented Merck in the transaction. Merck closed its exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd., to...
Entrada Therapeutics’ Global Collaboration with Vertex Pharmaceuticals Incorporated
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
Envisagenics’ Research Collaboration Agreement with Bristol Myers Squibb Company
Goodwin Procter advised Envisagenics, Inc. on the deal. Envisagenics, Inc. announced a research collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The multi-year collaboration will leverage...
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...